{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:55:12Z","timestamp":1762206912509,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"School of Medicine, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000853","name":"University of Glasgow","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008476","name":"University of California, Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012304","name":"School of Medicine, Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001545","name":"Children's Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jid.2022.11.027","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T18:36:08Z","timestamp":1687372568000},"page":"1351-1357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas"],"prefix":"10.1016","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0993","authenticated-orcid":false,"given":"Jaishri O.","family":"Blakeley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-5382","authenticated-orcid":false,"given":"Lu Q.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-8316","authenticated-orcid":false,"given":"Sang Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-2946","authenticated-orcid":false,"given":"Ina","family":"Ly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6551-8631","authenticated-orcid":false,"given":"Steven D.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0260-7047","authenticated-orcid":false,"given":"Carlos G.","family":"Romo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-3053","authenticated-orcid":false,"given":"Kavita Y.","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-5585","authenticated-orcid":false,"given":"Verena","family":"Staedtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9003-6730","authenticated-orcid":false,"given":"Matthew R.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-457X","authenticated-orcid":false,"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Largaespada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzlifah","family":"Haniffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross L.","family":"Cagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anat","family":"Stemmer-Rachamimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Topilko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna","family":"Kornacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Gottesman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"York","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roselyn","family":"Epps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2022.11.027_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaip.2022.09.021","article-title":"Impact of a decade of research into atopic dermatitis","volume":"11","author":"Arkwright","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jid.2022.11.027_bib2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Bollag","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2022.11.027_bib3","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.1038\/s41467-018-07452-y","article-title":"NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation","volume":"9","author":"Brosseau","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2022.11.027_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13023-018-0772-z","article-title":"Cutaneous neurofibromas in neurofibromatosis type I: A quantitative natural history study","volume":"13","author":"Cannon","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2022.11.027_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.1986.tb48061.x","article-title":"The genetic aspects of neurofibromatosis","volume":"486","author":"Carey","year":"1986","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jid.2022.11.027_bib6","first-page":"i107","article-title":"Management of cutaneous neurofibroma: current therapy and future directions","volume":"2","author":"Chamseddin","year":"2020","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.jid.2022.11.027_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-18-0151","article-title":"Spatiotemporal loss of NF1 in Schwann cell lineage leads to different types of cutaneous neurofibroma susceptible to modification by the hippo pathway","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2022.11.027_bib8","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2022.11.027_bib9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: A cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/aja.1001950307","article-title":"Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development","volume":"195","author":"Daston","year":"1992","journal-title":"Dev Dyn"},{"key":"10.1016\/j.jid.2022.11.027_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R","article-title":"Neurofibromatosis type 1 and pregnancy","volume":"66","author":"Dugoff","year":"1996","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.jid.2022.11.027_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/1346-8138.14025","article-title":"Natural course and characteristics of cutaneous neurofibromas in neurofibromatosis 1","volume":"45","author":"Ehara","year":"2018","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib13","article-title":"Whole exome sequencing of growing and non-growing cutaneous neurofibromas from a single patient with neurofibromatosis type 1","volume":"12","author":"Faden","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.11.027_bib14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","article-title":"A\u00a0phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: A pediatric brain tumor consortium study","volume":"23","author":"Fangusaro","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jid.2022.11.027_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.45","article-title":"A\u00a0high-throughput molecular data resource for cutaneous neurofibromas","volume":"4","author":"Gosline","year":"2017","journal-title":"Sci Data"},{"key":"10.1016\/j.jid.2022.11.027_bib16","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2022.11.027_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13023-019-1265-4","article-title":"Cutaneous neurofibromas: patients' medical burden, current management and therapeutic expectations: results from an online European patient community survey","volume":"14","author":"Guiraud","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jid.2022.11.027_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imlet.2020.12.006","article-title":"Immuno-hippo: research progress of the hippo pathway in autoimmune disease","volume":"230","author":"Guo","year":"2021","journal-title":"Immunol Lett"},{"key":"10.1016\/j.jid.2022.11.027_bib19","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence\u00a0and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib20","first-page":"1319","article-title":"Cutaneous neurofibroma cells with active YAP promotes proliferation of macrophages resulting in increased accumulation of macrophages by modulating CCL5 and TGF-\u03b21","volume":"43","author":"Jia","year":"2020","journal-title":"Oncol Rep"},{"key":"10.1016\/j.jid.2022.11.027_bib21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jid.2022.12.027","article-title":"Cutaneous neurofibroma heterogeneity: factors that influence tumor burden in neurofibromatosis type 1","volume":"143","author":"Jiang","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000517011","article-title":"Mast cells in human cutaneous neurofibromas: density, subtypes, and association with clinical features in neurofibromatosis 1","volume":"238","author":"Kallionp\u00e4\u00e4","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2022.11.027_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jid.2021.06.033","article-title":"Differences in psychometric properties of clinician- and patient-reported outcome measures for atopic dermatitis by race and skin tone: A systematic review","volume":"142","author":"Kaundinya","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008920","article-title":"Developmental loss of neurofibromin across distributed neuronal circuits drives\u00a0excessive grooming in Drosophila","volume":"16","author":"King","year":"2020","journal-title":"PLoS Genet"},{"key":"10.1016\/j.jid.2022.11.027_bib25","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10103-013-1469-0","article-title":"Comparative study of CO2- and er:YAG laser ablation of multiple cutaneous neurofibromas in von Recklinghausen's disease","volume":"29","author":"Kriechbaumer","year":"2014","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.jid.2022.11.027_bib26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","article-title":"Immortalization of human normal and NF1 neurofibroma Schwann cells","volume":"96","author":"Li","year":"2016","journal-title":"Lab Invest"},{"key":"10.1016\/j.jid.2022.11.027_bib27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jid.2023.03.1681","article-title":"Current and emerging imaging techniques for neurofibromatosis type 1\u2013associated cutaneous neurofibromas","volume":"143","author":"Li","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib28","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1172\/JCI99424","article-title":"Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis","volume":"128","author":"Liao","year":"2018","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2022.11.027_bib29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jid.2023.01.041","article-title":"Target product profile for cutaneous neurofibromas: clinical trials to prevent, arrest, or regress cutaneous neurofibromas","volume":"143","author":"Ly","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib30","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.0000000000012427","article-title":"Measuring the effect of cutaneous neurofibromas on quality of life in neurofibromatosis type 1","volume":"97","author":"Maguiness","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2022.11.027_bib31","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.jisp.2017.10.005","article-title":"Cytokine targeted therapeutics for alopecia areata: lessons from atopic dermatitis and other inflammatory skin diseases","volume":"19","author":"Malik","year":"2018","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jid.2022.11.027_bib32","article-title":"Refining nosology by modelling variation among facial phenotypes: the RASopathies [epub ahead of print]","author":"Matthews","year":"2022","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.jid.2022.11.027_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.102068","article-title":"Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: reprogramming plexiform neurofibroma cells","volume":"49","author":"Mazuelas","year":"2020","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.jid.2022.11.027_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2340\/00015555-2940","article-title":"Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study","volume":"98","author":"Misery","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2022.11.027_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139807","article-title":"Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins","volume":"131","author":"Mo","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2022.11.027_bib36","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1212\/WNL.0000000000005792","article-title":"Cutaneous neurofibromas: current clinical and pathologic issues","volume":"91","author":"Ortonne","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2022.11.027_bib37","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of Ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11010-017-3227-2","article-title":"The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1+\/- or NF1-\/- genotype derived from human cutaneous neurofibromas","volume":"444","author":"Pennanen","year":"2018","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.jid.2022.11.027_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","article-title":"Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells","volume":"9","author":"Radomska","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2022.11.027_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjd.21696","article-title":"Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes","volume":"187","author":"Renert-Yuval","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib41","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jid.2023.01.043","article-title":"RAS signaling gone awry in the skin: the complex role of RAS in cutaneous neurofibroma pathogenesis, emerging biological insights","volume":"143","author":"Rhodes","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216527","article-title":"The evolution and multi-molecular properties of NF1 cutaneous neurofibromas originating from C-fiber sensory endings and terminal Schwann cells at normal sites of sensory terminations in the skin","volume":"14","author":"Rice","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2022.11.027_bib43","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2022.11.027_bib44","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/ajcp\/aqaa186","article-title":"A\u00a0clinicopathologic study on the role of estrogen, progesterone, and their classical and nonclassical receptors in cutaneous neurofibromas of individuals with neurofibromatosis 1","volume":"155","author":"Rozza-de-Menezes","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jid.2022.11.027_bib45","article-title":"FDA approves Ruxolitinib (opzelura) for vitiligo therapy: A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.jid.2022.11.027_bib46","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jid.2023.01.042","article-title":"Existing and developing preclinical models for neurofibromatosis type 1\u2013related cutaneous neurofibromas","volume":"143","author":"Staedtke","year":"2023","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib47","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev-pathol-011811-132441","article-title":"Pathogenesis of plexiform neurofibroma: tumor-stromal\/hematopoietic interactions in tumor progression","volume":"7","author":"Staser","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jid.2022.11.027_bib48","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-03-4079","article-title":"Comparative pathology of nerve sheath tumors in mouse models and humans","volume":"64","author":"Stemmer-Rachamimov","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2022.11.027_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s004390050317","article-title":"Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene","volume":"99","author":"Upadhyaya","year":"1997","journal-title":"Hum Genet"},{"key":"10.1016\/j.jid.2022.11.027_bib50","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1212\/WNL.0000000000005791","article-title":"Considerations for development of therapies for cutaneous neurofibroma","volume":"91","author":"Verma","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.jid.2022.11.027_bib51","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"JAK inhibitors for treatment of alopecia areata","volume":"138","author":"Wang","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2022.11.027_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232031","article-title":"The effect of pregnancy on growth-dynamics of neurofibromas in neurofibromatosis type 1","volume":"15","author":"Well","year":"2020","journal-title":"PLoS One"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23019838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:52:55Z","timestamp":1762206775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23019838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0022202X23019838"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2022.11.027","relation":{},"ISSN":["0022-202X"],"issn-type":[{"type":"print","value":"0022-202X"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2022.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}